The purpose of this study is to compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL according to the delivery device.

Inclusion Criteria:

• Adult patients (≥ 18 years)
• Presenting with primary immunodeficiency
• Having received subcutaneous injections of immunoglobulin at home using an automatic pump for at least 1 month at the time of inclusion
• For whom the investigator decides to maintain immunoglobulin replacement therapy with subcutaneous injections of Gammanorm® 165 mg/mL at home
• Having signed an informed consent form

Exclusion Criteria:

• Patient currently participating in another interventional study at the time of inclusion